-
Article
Open AccessReporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials
Tumour biopsy for pharmacodynamic (PD) study is increasingly common in early-phase cancer trials. As they are non-diagnostic, the ethical justification for such procedures rests on their knowledge value. On th...
-
Article
Open AccessA phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to evaluate the efficacy, safety and pharmacodynamics ...
-
Article
Open AccessPhase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer...
-
Article
Open AccessA phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a common malignant tumour, which has a poor prognosis. Surgical resection can be curative but most patients are inoperable and most chemotherapy agents have minimal activity i...
-
Chapter
Cancer Drugs and Cancer Drug Development for the New Millennium
Most chemotherapeutic agents used today were identified by empirically screening natural products or synthetic compounds for cytotoxic potency in vitro against murine and/or human cancer cell lines and in vivo...
-
Article
A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)
Cisplatin-based combination chemotherapy is frequently used to treat patients with carcinoma of unknown primary site (CUPS). Response rates in the literature range from 12% to 26% and median survival from 5 to...
-
Article
Current perspectives on camptothecins in cancer treatment
The camptothecins are a new class of chemotherapeutic agents which have a novel mechanism of action targeting the nuclear enzyme topoisomerase I. Knowledge of the structure-activity relationships of the parent...